Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00284271

Enrollment

Registered

2006-01-31

Start date

2004-01-31

Completion date

Unknown

Last updated

2011-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin´s Lymphoma

Keywords

Hodgkin´s Lymphoma, eldery patients, primary diagnosis

Brief summary

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Interventions

DRUGCyclophosphamide

DRUGAdramycin

DRUGProcarbacine

DRUGPrednisone

DRUGVincristine

DRUGBleomycin

DRUGErythropoietin beta

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

61 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Hodgkin´s lymphoma (histologically proven) * CS (PS) I and II with one of the risk factors a-d 1. bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR \> 50 (A), \> 30 (B-symptoms) 4. 3 or more lymph node areas involved * CS (PS) III and IV * Written informed consent

Exclusion criteria

* Leukocytes \<3000/microl * Platelets \<100000/microl * Hodgkin´s Disease as composite lymphoma * Activity index (WHO) \< grade 2

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026